BÜHLMANN Laboratories AG products

The Quantum Blue^® Adalimumab assay measures from 1.3 to 35 µg/ml. The target concentrations for the optimal therapeutic window lies well within the linear range of the test. Quantum Blue^® Adalimumab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately while following up the patient’s therapy. Quantum Blue^® Adalimumab is unique in the diagnostics market, being the only test that can provide fast, reliable TDM for adalimumab and it correlates well with the standard routine ELISAs for adalimumab level determinations.

The Quantum Blue^® Infliximab assay measures from 0.4 to 20 µg/mL. The target concentrations for trough level interpretation lies well within the linear range of the test. Quantum Blue^® Infliximab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately before infusion of the next infliximab dose. Quantum Blue^® Infliximab is unique in the diagnostics market, being the only test that can provide fast, reliable TDM for infliximab and it correlates well with the standard routine ELISAs for infliximab level determinations.

The production of melatonin is inhibited by daylight and occurs during darkness. Thus, melatonin levels are very low during day and rise in the evening. Melatonin is a conservative Molecule and as such is ubiquitous. Not only has it been described in humans and animals, but also in plants and even in microorganisms.

The anti-SGPG Autoantibodies ELISA by BÜHLMANN is a semi-quantitative assay for determining IgM antibodies against SGPG. Anti-SGPG antibodies have a wider spectrum than anti-MAG antibodies: some patients which are anti-SGPG positive are negative for anti-MAG antibodies. Therefore, combined testing enhances sensitivity. The presence of anti-MAG/anti-SGPG antibodies is suggestive of a demyelinating neuropathy, whereas the presence of anti-SGPG antibodies alone seems to be more present in axonal non-demyelinating neuropathies, often of predominantly motor-type.

The anti-MAG Autoantibodies ELISA has outstanding sensitivity and specificity. In a study with 68 involved patients, the anti-MAG Autoantibodies ELISA was considerably more sensitive compared to Western Blot (Kuijf M. et al., 2009). High titers of IgM anti-MAG antibodies are associated with sensory motor demyelinating peripheral neuropathy. The possibility of MAG antibody involvement in a suspected neuropathy may essentially be ruled out if a MAG IgM negative result is obtained. Detection of MAG IgM antibodies by ELISA based on human MAG antigen is significantly more sensitive and specific than Western Blot or IFA assays using primate antigen (Jaskowsky T. et al., 2008; Kuijf M. et al., 2009).